Caveats for biotech: Biotech normally starts to run in these times each year.
However this year we see some more shorting than in past years. In part this maybe be due to lower economic growth, budget cuts (think reimbursement) and risk capital being scarce.
So time will tell wether biotech stock can get their momentum as they used to.
Personally focussing a little bit more on company with actual revene and profit potential , even for trades.